EMA Refused: Dexxience (betrixaban maleate) — Portola Pharma UK Limited

View source ↗

Summary

EMA refused Dexxience (betrixaban) application for venous thromboembolism therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Dexxience (betrixaban maleate)

Snippet

Status: Refused. Therapeutic area: Venous Thromboembolism. MAH: Portola Pharma UK Limited. Decision date: 20/09/2018